Aura Biosciences, Inc. · NASDAQ:AURA
Aura Biosciences — EURETINA 2022
12 slides from Aura Biosciences's conference presentation, September 2022
Slide 1: Clinical Evaluation of Belzupacap Sarotalocan (AU-011) for Choroidal Melanoma
Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a EURETINA First-in-Class Targeted Therapy for Choroidal Melanoma 2022 with Intravitreal or Suprachoroidal Route of Administration Martine Jager, MD, PhD Leiden University
Slide 2: Targeted Oncology Platform - Virus-Like Drug Conjugates (VDCs)
Targeted Oncology Platform - Virus-Like Drug Conjugates (VDCs) Virus-Like Particles Conjugated to a Cytotoxic Payload to VDCs can Recognize Tumor Associated HSPGs* form the VDC Cx Virus-Like Particle (VLP) Cytotoxic Drug Virus-Like Drug Conjugate (VDC) Technology Platform Designed to Target a Broad
Slide 3: Belzupacap Sarotalocan (AU-011) is a VDC with a Novel Dual Mechanism of Action
Belzupacap Sarotalocan (AU-011) is a VDC with a Novel Dual Mechanism of Action Light Activated Drug Belzupacap Sarotalocan Belzupacap sarotalocan is a novel VDC that consists of a VLP conjugated to ~200 molecules of phthalocyanine dye Potential Key Differentiation: Physical Ablation May Reduce Risk
Slide 4: Completed Phase 1b/2 – Key Patient Populations and Objectives
Completed Phase 1b/2* – Key Patient Populations and Objectives Primary Objective: Safety All Patients Enrolled with Clinical Diagnosis of Choroidal Melanoma or Indeterminate Lesions Drug or treatment related adverse events Safety Evaluation Efficacy Evaluation (AEs) / serious adverse events (SAEs)
Slide 5: Phase 1b/2 – Tumor Control Achieved with Therapeutic Regimen
Phase 1b/2 – Tumor Control Achieved with Therapeutic Regimen Tumor Control Rate at 12 months All Patients with Small Tumors with Active Growth Total Patients Tumor Control Rate Populations (n) (at 12 months) Treated with 2 Cycles (n=14) All Doses/Regimens All Treated Patients 56 54% (30/56) Lower Do
Slide 6: Phase 1b/2 – Statistically Significant Growth Rate Reduction
Phase 1b/2 – Statistically Significant Growth Rate Reduction Change in Tumor Growth (mm/yr) Change in Tumor Growth Small Tumors with Active Growth (n=14) Follow up 12 months AU-011 Historical Growth Rate Growth Rate n Growth Rate (mm/yr) Reduction p-value (mm/yr) (mm/yr) 12 months * Active Growth/Th
Slide 7: Phase 1b/2 – Visual Acuity was Preserved in Majority of Patients
Phase 1b/2 – Visual Acuity was Preserved in Majority of Patients Vision Preservation Rates Follow up 12 months Vision Preservation Rate Vision loss was transient but recovered in Total Patients Failure: Long term most patients after inflammation or Populations (n) loss ≥15 letters transient AEs re
Slide 8: Ph 1b/2 Safety: Belzupacap Sarotalocan was Well Tolerated
Ph 1b/2 Safety: Belzupacap Sarotalocan was Well Tolerated Majority of Adverse Events (AEs) were Transient and Managed with Standard of Care Treatment All Treated Subjects (n=56) Grade I Grade II Grade III Total Key Treatment Related Adverse Events (≥10% Subjects) Vitreous Inflammation 25% 58.
Slide 9: Suprachoroidal Administration Optimizes Delivery to the Posterior Segment
Suprachoroidal Administration Optimizes Delivery to the Posterior Segment – More Targeted Delivery to the Tumor OcularOcular Exposure After IVT or SC Injection* Exposure After IVT or SC Injection 20000 IVT AU-011 Concentration (ng/mL) SC 15000 10000 Intravitreal (IVT) injection Suprachoroidal (SC) i
Slide 10: Evaluating Suprachoroidal Administration to Determine Optimal Administration Route for Pivotal Trial
Evaluating Suprachoroidal Administration to Determine Optimal Administration Route for Pivotal Trial Ph 2 SC Trial Design: Dose Escalation Phase 18 subjects enrolled ▪ Cohort 6 currently enrolling Single Dose Cohorts – Completed 20 μg 40 μg 40 μg ▪ 80µg dose and 3 cycles of therapy x 1 Laser x 1 Las
Slide 11: Phase 2 SC – Demonstrated Favorable Safety Profile To Date
Phase 2 SC – Demonstrated Favorable Safety Profile To Date Preliminary results All Treated Subjects (n=18) Treatment Related Adverse Events (>5%) Grade I Grade II Grade III Total • Majority of AEs were transient and resolved without clinical sequelae Anterior chamber cell/ inflammation 22.2% 0 0 22.
Slide 12: Belzupacap Sarotalocan Ocular Oncology Development Program
Belzupacap Sarotalocan Ocular Oncology Development Program Choroidal Melanoma Choroidal Metastasis (CMets) In Combination with ICIs* Demonstrated safety and Dose-dependent activity in vivo Belzupacap sarotalocan plus efficacy with IVT and safety with using syngeneic mouse models ICIs (anti-PD-L1 & a